About Kyttaro Therapeutics
Kyttaro Therapeutics is a company based in New York (United States) founded in 2021. It operates as a B2B. Kyttaro Therapeutics offers products and services including MSC-AAT, MSC-Cyt, and MSC-Klotho. Kyttaro Therapeutics operates in a competitive market with competitors including Mesoblast, RoosterBio, SanBio, BrainStorm Cell and SCM Lifescience, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kyttaro Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kyttaro Therapeutics
Kyttaro Therapeutics offers a comprehensive portfolio of products and services, including MSC-AAT, MSC-Cyt, and MSC-Klotho.
Treats diseases using genetically modified stem cells for alpha-1 antitrypsin.
Develops cytokine-based stem cell therapies for various medical conditions.
Focuses on stem cell modifications for treating kidney and related diseases.
Funding Insights of Kyttaro Therapeutics
Detailed funding history for Kyttaro Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kyttaro Therapeutics
Investment portfolio details for Kyttaro Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kyttaro Therapeutics
Detailed financials for Kyttaro Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kyttaro Therapeutics Comparisons
Peer comparison for Kyttaro Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kyttaro Therapeutics
Kyttaro Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mesoblast, RoosterBio, SanBio, BrainStorm Cell and SCM Lifescience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| Locked | Locked | Locked |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| Locked | Locked | Locked |
Regenerative cell medicines for neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD
|
|
| Locked | Locked | Locked |
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
|
|
| Locked | Locked | Locked |
Cellular therapeutics are developed for cancer, orthopaedics, and COPD.
|
Detailed competitors of Kyttaro Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kyttaro Therapeutics
Complete news archive for Kyttaro Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kyttaro Therapeutics
Kyttaro Therapeutics was founded in 2021.
Kyttaro Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Kyttaro Therapeutics is a platform technology company specializing in genetically modified mesenchymal stem cells for clinical applications. It holds patents for treatments like MSC-AAT, MSC-Cyt, and MSC-Klotho, targeting diseases such as Graft Vs. Host Disease and Type 1 Diabetes. Based on 15 years of research in Germany and worldwide, the company focuses on preclinical evaluations and upcoming clinical trials in Europe and the US. It partners with investors to advance therapies for patients with high unmet medical needs.
Kyttaro Therapeutics's top competitors include RoosterBio, Mesoblast and SanBio.
Kyttaro Therapeutics offers MSC-AAT, MSC-Cyt, and MSC-Klotho.